Skip to content
Catalyst

PapersPMID:35447899

Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.

Marine drugs2022The record ↗

  1. Finding, very limited evidencelowersTLR4

What moved

1 findingHow to read these marks →
  • Inhibits TLR4

    very limited

    “The expression of TLR4 and its downstream proteins myeloid differentiation factor 88 (MyD88), p-IκBα, and p-NF-κBp65 was significantly upregulated in the FFA group, and was significantly inhibited by treatment with fucoxanthin.”
    Study
    in vitro · not in humans
    Population
    Human Chang liver cell line, FFA-induced NAFLD cell model, fucoxanthin group

Study record

Design
in vitro
Species
cells
Population
Human Chang liver cell line, free-fatty-acid (oleate/palmitate 2:1, 1 mM, 24 h)-induced nonalcoholic fatty liver disease (NAFLD) cell model
Participants
not reported
Comparator
placebo / within arm
Duration
1 day
Endpoints measured
8